392P Quality-adjusted Time Without Symptoms of Disease Progression or Toxicity of Treatment (Q-Twist) Analysis to Assess Benefit-Risk of Sacituzumab Govitecan (SG) in Previously Treated Patients (pts) with Metastatic Triple-Negative Breast Cancer (Mtnbc)

A.M. Brufsky, A. Bardia,M.S. Sedrak, S. Loibl, S.M. Tolaney,K. Punie, S.A. Hurvitz, K. Kalinsky, J. Cortés, J. O'Shaughnessy,V.C. Dieras, M. Piccart, A. Dasgupta, A.G. Kaushik, C. Lai, L. Shi, H.S. Rugo

Annals of Oncology（2024）

Cited 0|Views2

No score

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined